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Abstract
The type II transmembrane serine proteases TMPRSS2 and HAT activate influenza viruses and the SARS-coronavirus
(TMPRSS2) in cell culture and may play an important role in viral spread and pathogenesis in the infected host. However, it is
at present largely unclear to what extent these proteases are expressed in viral target cells in human tissues. Here, we show
that both HAT and TMPRSS2 are coexpressed with 2,6-linked sialic acids, the major receptor determinant of human
influenza viruses, throughout the human respiratory tract. Similarly, coexpression of ACE2, the SARS-coronavirus receptor,
and TMPRSS2 was frequently found in the upper and lower aerodigestive tract, with the exception of the vocal folds,
epiglottis and trachea. Finally, activation of influenza virus was conserved between human, avian and porcine TMPRSS2,
suggesting that this protease might activate influenza virus in reservoir-, intermediate- and human hosts. In sum, our results
show that TMPRSS2 and HAT are expressed by important influenza and SARS-coronavirus target cells and could thus
support viral spread in the human host.
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Introduction
Influenza viruses and the SARS-coronavirus (SARS-CoV) are
highly transmissible respiratory viruses which pose a serious threat
to human health. The yearly recurring influenza epidemics are
associated with significant morbidity and mortality, particularly
among the elderly, and the global spread of pandemic influenza
viruses can cause millions of deaths [1]. The severe acute
respiratory syndrome coronavirus (SARS-CoV), which causes a
novel lung disease, SARS, emerged in 2002 and spread to 26
countries in 2003, with 774 fatal infections [2]. Both SARS-CoV
and influenza viruses circulate in animal reservoirs, water fowl
(influenza) and bats (SARS-CoV) [3,4]. Therefore, the identifica-
tion of cellular factors essential for viral spread in animal and
human cells should allow novel approaches to prevention and
therapy.
The SARS-CoV spike protein (SARS-S) and the influenza virus
hemagglutinin (HA) are inserted into the viral membranes and
mediate host cell entry. For this, SARS-S and influenza HA bind
to host cell receptors, ACE2 (SARS-CoV) [5] and 2,6-linked sialic
acid on membrane proteins or lipids (human influenza viruses) [6],
and mediate the fusion of the viral membrane with a host cell
membrane. As a consequence, viral components are released into
the host cell and can subvert the synthetic capabilities of the host
cell for production and release of progeny particles.
The influenza HA and the SARS-S-protein are both synthe-
sized as inactive precursors which transit into their active forms
upon cleavage by host cell proteases. Cleavage of SARS-S and
influenza HA is essential for viral infectivity and the responsible
proteases are targets for antiviral intervention [7,8], but their
nature is incompletely defined. Recent evidence indicates that the
type II transmembrane serine proteases (TTSPs) TMPRSS2,
TMPRSS4 and HAT can activate human influenza viruses for
spread in protease transfected cells [4,9,10]. In addition,
endogenous TMPRSS2 was shown to promote influenza virus
spread in the cell lines Caco-2 and Calu-3 [11,12]. The SARS-
CoV was found to be activated by cathepsin L upon viral uptake
into host cell endosomes [8]. However, several recent reports
demonstrated that expression of TMPRSS2 in target cells
rendered cathepsin activity dispensable for infectious entry of
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35876SARS-CoV [13–15], suggesting that both SARS-CoV and
influenza viruses can exploit TTSPs to promote their spread.
Despite the intriguing findings made in cell culture, the role of
TMPRSS2 and HAT in influenza virus and SARS-CoV spread
and pathogenesis remains to be defined. For this, it is essential to
determine the extent of TMPRSS2 and HAT expression in viral
target cells in human tissues. Here, we show that TMPRSS2 and
HAT are coexpressed with ACE2 and 2,6-linked sialic acids, the
key receptor determinants of SARS-CoV and influenza virus,
respectively, in major portions of the human respiratory tract,
indicating that these proteases could support SARS-CoV and
influenza virus spread in humans. In addition, we demonstrate
that HA activation is conserved between human TMPRSS2 and
TMPRSS2 of animal species critically involved in zoonotic
transmission of influenza virus, underlining a potentially important
role of this protease in the influenza virus zoonosis.
Materials and Methods
Cell culture
293T cells were obtained from the American Type Culture
Collection (ATCC) and were propagated in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), penicillin and streptomycin, and grown in a
humidified atmosphere of 5% CO2.
Cell-cell fusion assay
For analysis of cell-cell fusion, 293T effector cells seeded in 6-
well plates were CaPO4-transfected with either empty pcDNA
plasmids or plasmids encoding SARS- S in combination with
plasmid pGAL4-VP16 encoding the Herpes Simplex transactiva-
tor VP16 fused to GAL4, as described [13]. In parallel, 293T
target cells were seeded in 48-well plates and transfected with
plasmids encoding the indicated proteases or empty plasmid
together with plasmid pGal5-luc, which encodes a promoter with
five Gal4 binding sites in front of a luciferase gene. Transfected
effector and target cells were mixed, incubated with trypsin or PBS
and fusion was quantified by determination of luciferase activities
in cell lysates 48 h after cocultivation using a commercially
available kit (Promega, Madison, USA).
Production of lentiviral pseudotypes and infection
experiments
For generation of lentiviral pseudoparticles, CaPO4 transfec-
tions were performed as described [13]. Briefly, 293T cells were
transiently cotransfected with pNL4-3 E-R- Luc [16] and
expression plasmids coding for influenza virus HA and neuramin-
idase (NA) or vesicular stomatitis virus glycoprotein (VSV-G) [10].
For analysis of HA activation by TTSPs, expression plasmids for
the indicated proteases [11,13] or empty vector were cotransfected
into cells producing pseudoparticles. The culture medium was
replaced at 16 h and harvested at 48 h post transfection. The
supernatants were passed through 0.45 mm filters and stored at
280uC. For infection, pseudoparticles were treated with either
PBS or trypsin followed by incubation with 293T target cells for
three days before cells were lysed and luciferase-activities
determined using a commercially available kit (Promega, Madison,
USA).
Analysis of SARS-S and 1918 HA cleavage
For the detection of HA and SARS-S-cleavage in cis, 293T cells
were cotransfected with plasmids encoding SARS-S [17] or 1918
HA and plasmids encoding the indicated proteases or empty
vector (pcDNA). For analysis of SARS-S cleavage in trans,
plasmids encoding SARS-S [17] and proteases were transfected
separately into 293T cells followed by mixing of the transfected
cells. Subsequently, the cells were treated with PBS or trypsin,
lysed, separated via 12,5% SDS-PAGE and transferred onto
nitrocellulose membranes. SARS-S was detected by staining with
rabbit serum raised against the S1 subunit of SARS-S subunit
[18]. For detection of HA, a mouse monoclonal antibody was used
[19]. As a loading control, the stripped membranes were
incubated with an anti-ß-actin antibody (Sigma, Deisenhofen,
Germany). Bound antibodies were detected with HRP-coupled
secondary antibodies (Dianova, Hamburg, Germany).
Immunostaining of tissue sections
Formalin fixed paraffin embedded tissue samples of a wide
range of tissues from the respiratory and gastrointestinal tracts, as
well as the myocardium, were obtained from the Oxford Radcliffe
Biobank, with full ethical approval from the National Research
and Ethics Service (Oxfordshire Research and Ethics Committee
A: reference 04/Q1604/21). While all patients gave generic
consent for the use of their tissue in research at the time of signing
a consent form for surgery, informed consent from each patient for
the use of tissue in this study was not required by the National
Research and Ethics Service, because all tissue was anonymised.
Tissue sections were immunostained for TMPRSS2, HAT and
ACE2 or with the elderberry lectin, Sambucus nigra, that detects 2,6-
linked sialic acids. Antigen retrieval was performed by pressure
cooking in different antigen retrieval solutions. Slides were
mounted in Aquatex mounting medium (Merck, UK). ACE2
immunostaining (affinity purified goat polyclonal serum, R&D
Systems, Abingdon, UK) was performed and detected using a
mouse anti-goat Ig (GTI-75) [20] and the Novolink
TM max
polymer detection system (Leica Microsystems, Newcastle, UK), as
per the manufacturer’s instructions after antigen retrieval in citrate
pH 6.0. TMPRSS2 (mouse monoclonal antibody P5H9 A3
ascites, a generous gift from Dr J.M. Lucas, Division of Human
Biology, Fred Hutchinson Cancer Research Center, Seattle, WA
98109, USA, [21]) immunostaining was detected using the
NovolinkTM max polymer detection system after antigen retrieval
in Tris EDTA pH9.0. HAT immunostaining (mouse monoclonal
antibody 337029, R&D Systems, Abingdon, UK) was performed
using the Novolink
TM max polymer detection system after antigen
retrieval in Dako Target retrieval solution pH 6.0 (Dako, Cam-
bridge, UK). Biotinylated elderberry lectin (Sambucus nigra)
(Vector labs, Peterborough, UK) binding was detected using
Streptavidin-HRP (Ar-Med Limited, Egham, UK) and detected
using Dako DAB chromogen substrate (Dako, Cambridge, UK)
after antigen retrieval in Tris-EDTA pH 9.0. Lung tissue was used
as a positive control for TMPRSS2, ACE2 and elderberry lectin
staining [11,13], while bronchus was used as a positive control for
HAT immunostaining [22]. As a negative control for ACE2
immunostaining and elderberry lectin staining, normal goat
polyclonal serum was substituted for the primary antibody/lectin
staining step. As a negative control for TMPRSS2 and HAT
immunostaining, an irrelevant mouse monoclonal (anti-ALK1
antibody, clone ALK1 [23]) was substituted for the primary
antibody. Stained sections were photographed with a Nikon DS-
FI1 camera with a Nikon DS-L2 control unit (Nikon UK Limited,
Kingston-upon-Thames, UK) and an Olympus BX40 microscope
(Olympus UK Limited, Watford, UK).
Results
Influenza viruses circulate in birds and poultry, with water fowl
constituting the natural reservoir, and coinfection of swine with
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the emergence of pandemic viruses [1,3]. TMPRSS2, TMPRSS4
and HAT were shown to activate influenza virus in transfected
cells [4,9,10], but only for TMPRSS2 further evidence for a
potential contribution to viral spread in humans was reported
[11,12]. In order to assess the role of TMPRSS2 in the influenza
virus zoonosis, we tested whether this protease derived from
chicken and swine is able to cleave HA. In parallel, we examined if
TMPRSS2 of mouse origin facilitates HA proteolysis, since mice
are commonly used as a model system for influenza virus spread
and pathogenesis. Finally, cleavage and activation of HA by
human and mouse HAT and TMPRSS4 were also evaluated.
Western blot analysis of transfected cells revealed that
TMPRSS2, TMPRSS4 and HAT of all animal species tested
cleaved the HA precursor HA0 and produced HA1 cleavage
fragments identical to those observed for the human enzymes
(Fig. 1A). The slightly faster migration of HA1 fragments
generated by TMPRSS2 compared to the other proteases is due
to differential HA glycosylation [11]. Cleavage resulted in HA
activation, since lentiviral vectors produced in the protease
expressing cells were fully infectious in the absence of trypsin
treatment (Fig. 1B). In contrast, no HA cleavage and activation
was observed in cells transfected with empty vector or cells
expressing human TMPRSS3 (Fig. 1A,B), which was previously
demonstrated not to process HA [11]. Similarly, swine, chicken
and mouse TMPRSS2 cleaved SARS-S into multiple fragments,
as previously documented for human TMPRSS2 [13], although
some variation in cleavage efficiency was noted (Fig. 1C). In
contrast, trypsin digestion produced the S1 subunit, as expected
[24,25]. Of note, SARS-S was cleaved by TMPRSS2 upon
coexpression of both proteins (cis cleavage, Figure 1C) and upon
mixing of SARS-S expressing cells with protease expressing cells
(trans cleavage, Fig. S1), although some variability in cleavage
efficiency was noted in the latter setting. In agreement with SARS-
S trans cleavage, expression of TMPRSS2 in target cells
(TMPRSS2 panels) endogenously expressing very low amounts
of viral receptor, ACE2 [5], allowed efficient SARS-S-driven cell-
cell fusion and fusion efficiency was not increased by the addition
of trypsin. In contrast, SARS-S-driven fusion with control
transfected cells (pcDNA panel) was inefficient and fusion
efficiency was rescued by trypsin treatment (Fig. 1D). Finally,
transfection of ACE2 plasmid into target cells (ACE2 panel) also
boosted cell-cell fusion and fusion efficiency was only modestly
increased by trypsin, in agreement with our previous finding that
receptor and protease expression on target cells can both limit
SARS-S-mediated cell-cell fusion [26]. In sum, these results
demonstrate that cleavage-activation of influenza HA and SARS-S
is conserved between human, porcine, avian and murine
TMPRSS2 as well as human and murine HAT. Our observations
also suggest that TMPRSS2 can support influenza virus spread in
species integral to the influenza zoonosis, and that mice are
suitable models to study the role of TMPRSS2, TMPRSS4 and
HAT in viral spread and pathogenesis.
Binding of human influenza viruses to 2,6-linked sialic acids
present on proteins and lipids on the host cell surface is critical for
infectious viral entry into host cells [6]. We assessed whether
TMPRSS2 and HAT are coexpressed with 2,6-linked sialic acid
human tissues. Immunostaining demonstrated the presence of 2,6-
linked sialic acids on the surface of almost all cell types (Fig. 2, 3,
4), in keeping with previous results [27–30], with the notable
exception of vascular smooth muscle cells (data not shown),
suggesting that expression of proteases, such as TMPRSS2 and
HAT, but not 2,6-linked sialic acid is likely to be a major
determinant of viral tropism. TMPRSS2 was expressed by
epithelial cells at all sites examined in the aerodigestive tracts, as
well as by many endothelial cells and myocytes of blood vessels,
leucocytes (including alveolar macrophages) and smooth muscle
cells (Fig. 2, 3, 4, table 1), indicating that TMPRSS2 could activate
influenza virus in most permissive epithelia. HAT showed a
distribution similar to TMPRSS2 (Fig. 2, 3, 4, table 1), but
immunostaining of pneumocytes (alveolar epithelial cells) was
weaker, implying low levels of protease expression at this site
(Fig. 2A, C). Unlike TMPRSS2, which appeared to be expressed
by the majority of type 2 pneumocytes, HAT was expressed by
fewer than 50% type 2 pneumocytes, but was additionally seen to
be expressed by occasional type 1 pneumocytes (Fig. 2A, C). Type
2 pneumocytes are defined by their morphology rather than a
particular immunophenotype, being plump rather than flattened
epithelial cells [31]. All sections were examined by an experienced
consultant pathologist (ES) in order to identify the cell types that
were immunopositive. The exact intensities of staining for
TMPRSS2 and HAT of various epithelial types in the aero-
digestive tracts are summarized in table 1. While TMPRSS2
expression by bronchial and intestinal smooth muscle cells was
noted, these cells appeared negative for HAT, although some
vascular smooth muscle cells were found to be positive (table 1).
Interestingly, TMPRSS2 but not HAT was expressed by cardiac
myocytes (Fig. 4), suggesting that influenza myocarditis might be
promoted by TMPRSS2 but not HAT. Notwithstanding, our data
demonstrate the potential importance of both proteases in
influenza infection.
TMPRSS2 on target cells activates SARS-S on adjacent cells for
cell-cell fusion and activates virion-associated SARS-S for
infectious host cell entry [13–15]. A wide range of sites
demonstrated coexpression of ACE2 and TMPRSS2, and could
thus support SARS-CoV spread (table 1). Specifically, in the lung
type 2, but not type 1 pneumocytes express both molecules, as do
alveolar macrophages and the epithelial cells of intrapulmonary
bronchi (Fig. 2A, B). In the upper respiratory tract, the epithelium
of the bronchi, larynx, nasal mucosa and respiratory sinuses (Fig. 2
E, F) expresses both molecules, while ACE2 expression is absent
from the trachea, vocal folds and epiglottis, although a previous
study by Ren et al demonstrated ACE2 expression on the surface
epithelium and mucus gland epithelium of trachea, similar to our
findings in the larynx and bronchus [32]. This suggests that ACE2
expression may be variable but widespread in the upper airway.
The epithelia of the tonsil (Fig. 3A, B) and buccal mucosa (Fig. 2E,
F) express both TMPRSS2 and ACE2. Additionally, ACE2
expression by some interstitial macrophages/dendritic cells in
intra-alveolar septa of the lung, adjacent to TMPRSS2-expressing
type 2 pneumocytes. In the gastrointestinal tract, epithelial co-
expression of TMPRSS2 and ACE2 was identified at all sites
examined, namely the oesophagus, stomach, ileum and colon. The
two molecules were also expressed in cardiac myocytes. Further-
more, variable expression of both molecules by endothelial cells
and myoctes of blood vessels, leucocytes and smooth muscle cells
was seen (Fig. 2, 3, 4, table 1). Taken together, these results suggest
that TMPRSS2 could promote SARS-CoV spread in important
target sites, the gastrointestinal and respiratory tracts (table 1).
Discussion
Influenza virus and SARS-CoV hijack host cell proteases to
acquire infectivity and for influenza it has been shown that broad
spectrum protease inhibitors have therapeutic potential [33–35].
However, the proteases responsible for viral activation in the
infected host are unclear, although several candidates have been
suggested [7,36]. Recent studies demonstrate that TMPRSS2 and
Proteolytic Activation of Influenza and SARS
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15,37] in cell culture. We show that both proteases are expressed
on receptor-positive cells throughout most of the human
respiratory tract and might thus support influenza virus and
SARS-CoV spread in and between individuals. In addition,
influenza virus activation was conserved between TMPRSS2
orthologues of human, porcine and avian origin, suggesting that
zoonotically transmitted influenza viruses may engage TMPRSS2
to facilitate their activation.
Figure 1. Proteolytic activation of influenza virus hemagglutinin and SARS spike protein is conserved between TMPRSS2 of human,
porcine, avian and murine origin. (A) Expression plasmids encoding the HA of the 1918 influenza virus and the indicated proteases or empty
vector (pcDNA) were transiently cotransfected into 293T cells. The cells were then treated with PBS or trypsin, and HA cleavage was detected by
Western blot analysis of cell lysates using a monoclonal antibody specific for HA. Detection of ß-actin served as loading control. (B) Lentiviral reporter
viruses bearing 1918 HA and NA or the VSV-G glycoproteins were generated in 293T cells coexpressing the indicated proteases or empty vector
(pcDNA), treated with PBS (black bars) or trypsin (white bars), and used for infection of 293T target cells. Viruses harboring no glycoprotein were
generated in parallel as control. Luciferase activities in the cell lysates were determined at 72 h post infection. The results of a representative
experiment performed in triplicates are shown. Error bars indicate standard deviation (SD). Comparable results were obtained in a separate
experiment. (C) To detect SARS-S cleavage in cis, expression plasmids coding for SARS-S and the indicated proteases or empty vector (pcDNA) were
transiently cotransfected into 293T cells, which were then treated with trypsin or PBS. Subsequently, S-protein cleavage was detected by Western blot
analysis of cell lysates using a serum specific for the S1 subunit of SARS-S. SARS-S cleavage fragments produced by trypsin and TMPRSS2 are indicated
by asterisks. Detection of ß-actin served as a loading control. (D) Effector 293T cells were cotransfected with a SARS-S expression plasmid and a
plasmid encoding GAL4-VP16 and mixed with target cells cotransfected with a plasmid encoding a GAL4-VP16 responsive luciferase expression
cassette and an ACE2 expression plasmid or protease expression plasmid or empty plasmid. The effector and target cells were mixed, treated with
PBS (black bars) or trypsin (white bars) and the luciferase activities in cell lysates quantified at 48 h after cell mixing. The results of a representative
experiment performed in triplicates are shown. Error bars indicate standard deviation (SD). Similar results were observed in two independent
experiments.
doi:10.1371/journal.pone.0035876.g001
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epithelium [38–40]. Spread in these tissues might be supported by
both TMPRSS2 and HAT, which we found to be expressed by
cells positive for 2,6-linked sialic acid in the nasal and buccal
mucosa as well as in the epithelium of trachea, bronchus and
larynx. If infection is associated with pneumonia, a complication
more frequently observed with pandemic compared to seasonal
influenza viruses, viral spread to the alveolar epithelium is
observed [38]. Type I pneumocytes have been suggested to be
major targets of influenza virus in the alveoli [40] and were found
to be positive for 2,6-linked sialic acid in this study. The protease
responsible for HA activation in these cells remains to be defined,
Figure 2. Pulmonary and respiratory sinus expression of SARS-
CoV and influenza virus activating proteases and receptors.
Lung (A–D) and sinus (E–H) tissue immunostained for TMPRSS2 (A&E),
ACE2 (B&F) and HAT (C&G), or stained for 2,6-linked sialic acid (D&H;
detected with elderberry (Sambucus nigra) lectin). All positive reactions
are detected with the peroxidase technique (brown) and the tissue is
counterstained with haematoxylin (blue). (A) There is strong positive
anti-TMPRSS2 immunostaining of bronchial epithelium (lining the
bronchus, marked Br), type 2 pneumocytes (P2) and alveolar
macrophages (Mp). (B) There is moderately strong positive anti-ACE2
immunostaining of bronchial epithelium (lining the bronchus, marked
Br), type 2 pneumocytes (P2) and alveolar macrophages (Mp). (C) There
is moderately positive anti-HAT immunostaining of bronchial epitheli-
um (lining the bronchus, marked Br) and alveolar macrophages (Mp),
with weakly positive immunostaining of some type 1 (P1) and type 2
pneumocytes (P2). (D) All structures are strongly stained for 2,6-sialic
acid except for smooth muscle (SM). (E) There is strong positive anti-
TMPRSS2 immunostaining of sinus epithelium (Ep) and lymphoid cells
(Ly). (F) There is strong positive anti-ACE2 immunostaining of sinus
epithelium (Ep) and lymphoid cells (Ly). (G) There is moderately strong
anti-HAT immunostaining of sinus epithelium (Ep) and occasional
weakly positive immunostaining of lymphoid cells (Ly). (H) All structures
are strongly stained for 2,6-sialic acid. Scale bar=50 microns (shown in
panels D and H and also pertaining to 3 preceding panels in each case).
doi:10.1371/journal.pone.0035876.g002
Figure 3. Tonsil and buccal mucosal expression of SARS-CoV
and influenza virus activating proteases and receptors. Tonsil
(A–D) and buccal mucosa (E–H) immunostained for TMPRSS2 (A&E),
ACE2 (B&F) and HAT (C&G), or stained for 2,6-linked sialic acid (D&H;
detected with elderberry (Sambucus nigra) lectin). All positive reactions
are detected with the peroxidase technique (brown) and the tissue is
counterstained with haematoxylin (blue). (A) There is strong positive
anti-TMPRSS2 immunostaining of tonsillar epithelium (Ep) and lympho-
cytes (Ly). (B) There is weakly positive anti-ACE2 immunostaining of
tonsillar epithelium (Ep), but little obvious positive immunostaining of
lymphocytes (Ly). (C) There is strongly positive anti-HAT immunostain-
ing of the basal and superficial, but not the middle, layers of tonsillar
epithelium (Ep), but little obvious positive immunostaining of
lymphocytes (Ly). (D) All structures are strongly stained for 2,6-sialic
acid except for a few areas of cells within the tonsillar epithelium (Ep).
(E) There is strong positive anti-TMPRSS2 immunostaining of buccal
epithelium (Ep) and of a blood vessel (BV) in the underlying connective
tissue (CT). (F) There is strong positive anti-ACE2 immunostaining of
buccal epithelium (Ep) and weaker positive immunostaining of a blood
vessel (BV) in the underlying connective tissue (CT). (G) There is strong
positive anti-HAT immunostaining of buccal epithelium (Ep), but a
blood vessel (BV) in the underlying connective tissue (CT) appears
negative. (H) All structures are strongly stained for 2,6-sialic acid. Scale
bar=50 microns (shown in panels D and H and also pertaining to 3
preceding panels in each case).
doi:10.1371/journal.pone.0035876.g003
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HAT was infrequent and weak. However, other studies found that
type II pneumocytes are preferentially infected [41] and these cells
were identified as positive for 2,6-linked sialic acid, TMPRSS2 and
occasionally for HAT within the present study. The presence of
cells positive for 2,6-linked sialic acid, TMPRSS2 and/or HAT
was not limited to the respiratory tract, in keeping with published
findings which demonstrate TMPRSS2 expression in the epithelia
of several organs [21,42–45]. It is therefore tempting to speculate
that TMPRSS2 and HAT might also support viral spread outside
the lung and might thus contribute to complications associated
with influenza infection, like gastrointestinal manifestations,
myocarditis and encephalopathy [38]. In sum, TMPRSS2 and,
with the exception of the alveolar epithelium, HAT could activate
influenza viruses throughout the respiratory tract and might
support viral spread in extra-respiratory tissues.
The mode of cleavage activation is a major virulence
determinant of avian influenza viruses [11,46–48]. Viruses with
a multi-basic cleavage site in HA are believed to be activated by
ubiquitously expressed host cell proteases and can thus replicate
systemically and cause severe disease [11]. In contrast, it has been
posited that replication of viruses with a mono-basic cleavage site
is confined to the aerodigestive tract, because the expression of as
yet unidentified HA-activating protease(s) is limited to this organ
[11]. Our results suggest that TMPRSS2 could be the elusive
protease, but it remains to be demonstrated whether TMPRSS2
expression in waterfowl and poultry is indeed specific for the
aerodigestive tract. HA activation was conserved between avian,
porcine and human TMPRSS2, which share high sequence
identity (see figure S2), indicating that TMPRSS2 might support
influenza virus spread not only in the reservoir (waterfowl) and
humans but also in an important intermediate host (swine).
The SARS-CoV causes a severe respiratory illness with fatal
outcome in about 10% of the afflicted individuals. The
metalloprotease ACE2 has been identified as the SARS-CoV
receptor and expression of ACE2 on type II pneumocytes, the
major viral target cells, and other pulmonary cells has been
demonstrated [49–52]. A cornerstone study by Simmons and
colleagues showed that infectious SARS-CoV entry into cell lines
depends on the activity of endosomal cathepins, particularly
cathepsin L [8], suggesting that cathepsin activity might be
required for viral spread in the respiratory tract. However, several
studies showed that TMPRSS2 activates SARS-CoV for cathep-
sin-independent host cell entry and demonstrated TMPRSS2
expression in type II pneumocytes [13–15]. In addition, a recent
report indicates that HAT can promote SARS-S-driven cell-cell
but not virus-cell fusion [37]. Thus, the SARS-CoV may use
TTSPs in addition to or instead of cathepsins to ensure its
activation in key target cells. Our analysis confirms and extends
these findings by demonstrating that ACE2 and TMPRSS2 are
coexpressed by cells in the nasal and buccal mucosa as well as in
the epithelia of bronchus and larynx. Thus, one can speculate that,
in the context of the infected host, cathepsin activity might not be
essential for SARS-CoV spread in most parts of the respiratory
tract. Experiments with cathepsin inhibitors and knock-out mice
are required to address this possibility. The gastrointestinal tract is
a well-established target of SARS-CoV [49] and it has actually
been suggested that a wide range of tissues and organs can be
infected by the virus [53]. Our finding that TMPRSS2 and ACE2
are coexpressed in colon and various other tissues indicates that
also the extrarespiratory spread of SARS-CoV might be promoted
by TMPRSS2.
Collectively, our findings are compatible with an important role
of TMPRSS2 and HAT in influenza virus and of TMPRSS2 in
SARS-coronavirus infection. Knock down of these proteases in
primary pulmonary cells and the analysis of Tmprss2 knock-out
mice would allow to precise definition of the role of these proteases
in viral spread. The latter animals are available [54] and do not
show an obvious phenotype, indicating that TMPRSS2 might be
an attractive target for novel drugs active against respiratory
viruses.
Figure 4. Ileal & myocardial expression of SARS-CoV and
influenza virus activating proteases and receptors. Ileum (A–D)
and myocardium (E–H) immunostained for TMPRSS2 (A&E), ACE2 (B&F)
and HAT (C&G), or stained for 2,6-linked sialic acid (D&H; detected with
elderberry (Sambucus nigra) lectin). All positive reactions are detected
with the peroxidase technique (brown) and the tissue is counterstained
with haematoxylin (blue). (A) There is strong positive anti-TMPRSS2
immunostaining of ileal epithelium (Ep) and also of lymphocytes (Ly)
within the core of the villus. (B) There is strong positive anti-ACE2
immunostaining of ileal epithelium (Ep) and also of lymphocytes (Ly)
within the core of the villus. (C) There is strongly positive anti-HAT
immunostaining of the basal part of the ileal epithelial cells (Ep), but
only weak positive immunostaining of occasional lymphocytes (Ly)
within the villus core. (D) All structures are strongly stained for 2,6-sialic
acid, including ileal epithelium (Ep) and lymphocytes (Ly). (E) There is
strong positive anti-TMPRSS2 immunostaining of cardiac myocytes. (F)
There is strong positive anti-ACE2 immunostaining of some cardiac
myocytes. (G) There is no anti-HAT immunostaining of cardiac
myocytes. (H) There is strong 2,6-sialic acid staining of cardiac
myocytes. Scale bar=50 microns (shown in panels D and H and also
pertaining to 3 preceding panels in each case).
doi:10.1371/journal.pone.0035876.g004
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Figure S1 To detect SARS-S cleavage in trans, expres-
sion plasmids coding for SARS-S and the indicated
proteases or empty vector (pcDNA) were separately
transfected into 293T cells. Subsequently, the SARS-S and
protease expressing cells were mixed, treated with trypsin or PBS
and S-protein cleavage was detected by Western blot analysis
using a serum specific for the S1 subunit of SARS-S. SARS-S
cleavage fragments produced by trypsin and TMPRSS2 are
indicated by asterisks. Detection of ß-actin served as a loading
control.
(TIF)
Figure S2 The amino acid sequences of TMPRSS2 of
human (NCBI Reference SequenceNP_001128571.1),
chicken (XM_416737.3), swine (BAF76737.1) and mouse
origin (AAF97867.1) were aligned using VectorNTI.
Identical amino acids are marked in black, similar
amino acids are marked in grey.
(TIF)
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Table 1. Expression pattern of influenza virus and SARS-coronavirus activating proteases and receptors in human tissues.
Antigen/site Cells/structure TMPRSS2 HAT ACE2 2,6-linked sialic acid
Lung Alveolar Epithelium type 2 not type 1
pneumocytes+
occasional type 2 & type 1
pneumocytes weakly+
type 2 not type 1 pneumocytes+ type 2 & type 1
pneumocytes+
Bronchial epithelium + +++
Alveolar macrophages + +++
Other interstitial macrophages/dendritic
cells+; bronchial smooth muscle
cells weakly+
some interstitial macrophages/
dendritic cells
+at all sites, except the
majority of smooth
muscle cells (SMC)
Bronchus &
Larynx
Epithelium +on respiratory,
glandular, transitional
and (weakly on)
squamous epithelium
+on respiratory, transitional and
squamous, but not glandular
epithelium
weakly+on respiratory &
transitional epithelium;
strongly+on glandular epithelium
+on respiratory,
glandular, transitional
and squamous
epithelium
Trachea Epithelium +on respiratory,
glandular, transitional
and (weakly on)
squamous epithelium
+on respiratory, transitional and
squamous, but not glandular
epithelium
2 +on respiratory,
glandular, transitional
and squamous
epithelium
Vocal folds &
epiglottis
Squamous epithelium weakly++ 2 +
Buccal mucosa Squamous epithelium + +++
Nasal mucosa &
respiratory
sinuses
Epithelium ++ respiratory & transitional
epithelium
+respiratory, transitional &
glandular epithelium
+
Lymphocytes + Occasionally+ Variably+ 2
Tonsil Squamous epithelium ++ weakly++
Lymphocytes + 22+
Oesophagus Squamous epithelium weakly++ weakly++
Stomach Epithelium ++ weakly++
Ileum Epithelium + weakly++ +
Colon Epithelium + weakly++ +
Myocardium Myocytes + 2 ++
Blood vessels Endothelial cells some weakly+ variably+ variably+ all+
Vascular smooth muscle
cells
+ variably+ variably+ 2
Leucocytes Lymphocytes + weakly+(negative in tonsil) +(negative in tonsil) +
Other leucocytes variably+ variably+ variably+ generally+
Smooth muscle
cells
Oesophagus, stomach,
intestine, bronchus
+ 2 + 2
Cell types expressing TMPRSS2, ACE2, HAT, 2,6-linked sialic acid are marked+, while those that do not express these molecules are marked2. ‘‘weakly’’ refers to a low
level of staining.
doi:10.1371/journal.pone.0035876.t001
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